Abstract:
Bacillus anthracis, the etiological agent of anthrax, is a spore- forming, toxin- producing bacterium. Currently, treatment of B. anthracis infections requires a 60- day antibiotic regimen. However, better therapeutics are required. Therefore, this study looked at the effect of levofloxacin and linezolid on B. anthracis cell viability, toxin production and spore formation using in vitro static models and a pharmacodynamic model. It was hypothesized that the combination would be the most effective at preventing toxin and spore production resulting in greater bacterial killing. However, these studies suggest otherwise. Nevertheless, clinically, the combination therapy may be more effective in rapid killing of vegetative B. anthracis and may be able to reduce the duration of therapy (by reducing the likelihood of spore survival). Therefore, the clinical benefit of combined therapy on long-term recurrence cannot be determined from these in vitro models. Further investigation with combination therapy is warranted.
